<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Drugs><Drug><Id>8050</Id><DrugType><Type>Small molecule therapeutic</Type></DrugType><DevelopmentStatusCurrent><Row><Company id="15331">Celgene Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2003-12-31T00:00:00Z</StatusDate><SourceLink type="PR" id="884216"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2010-11-01T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1200248"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2009-08-24T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1425442"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2008-04-21T00:00:00Z</StatusDate><SourceLink type="PR" id="898511"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2009-10-19T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1350018"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2017-04-03T00:00:00Z</StatusDate><SourceLink type="OTHER" id="2125671"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2008-11-01T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1388862"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2007-01-31T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="1109203"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2008-12-19T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1414633"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2008-09-01T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1355435"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2006-12-31T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="785341"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="219">Mycobacterium leprae infection</Indication><StatusDate>2003-12-31T00:00:00Z</StatusDate><SourceLink type="PR" id="884216"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="219">Mycobacterium leprae infection</Indication><StatusDate>2017-04-03T00:00:00Z</StatusDate><SourceLink type="OTHER" id="2125671"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="219">Mycobacterium leprae infection</Indication><StatusDate>1998-10-01T00:00:00Z</StatusDate><SourceLink type="PR" id="300125"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2006-01-10T00:00:00Z</StatusDate><SourceLink type="PR" id="884216"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2006-12-12T00:00:00Z</StatusDate><SourceLink type="PR" id="884216"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2006-01-10T00:00:00Z</StatusDate><SourceLink type="PR" id="884216"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="10">AIDS related complex</Indication><StatusDate>2001-05-13T00:00:00Z</StatusDate></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="1143">Amyloidosis</Indication><StatusDate>2004-03-15T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="587744"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="768">Behcets disease</Indication><StatusDate>1999-03-26T00:00:00Z</StatusDate><SourceLink type="PR" id="264366"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2014-10-31T00:00:00Z</StatusDate></Row><Row><Company id="15331">Celgene Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2004-03-15T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="587744"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2004-03-15T00:00:00Z</StatusDate><SourceLink type="PR" id="884216"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2004-03-15T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="587744"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate>2001-07-28T00:00:00Z</StatusDate><SourceLink type="PR" id="264366"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="2454">Glioblastoma</Indication><StatusDate>2011-04-30T00:00:00Z</StatusDate></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2004-03-15T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="587744"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2006-04-28T00:00:00Z</StatusDate></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="1264">Macroglobulinemia</Indication><StatusDate>2014-04-30T00:00:00Z</StatusDate></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate>2009-02-03T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="981117"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2005-01-01T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="591340"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="EU">EU</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="219">Mycobacterium leprae infection</Indication><StatusDate>2005-11-30T00:00:00Z</StatusDate></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate>2006-04-28T00:00:00Z</StatusDate></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2005-03-01T00:00:00Z</StatusDate></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2006-04-28T00:00:00Z</StatusDate></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>1996-07-29T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="177618"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2007-12-31T00:00:00Z</StatusDate></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate>2001-11-25T00:00:00Z</StatusDate><SourceLink type="PR" id="368433"/></Row></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Row><Company id="29253">Pharmion Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortorder="15">Launched</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2003-12-31T00:00:00Z</StatusDate><SourceLink type="PR" id="523013"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2010-08-04T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="1172389"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2008-04-21T00:00:00Z</StatusDate><SourceLink type="PR" id="898511"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2003-12-18T00:00:00Z</StatusDate><SourceLink type="PR" id="884216"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2006-12-12T00:00:00Z</StatusDate><SourceLink type="PR" id="750924"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2006-05-25T00:00:00Z</StatusDate><SourceLink type="PR" id="669679"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="219">Mycobacterium leprae infection</Indication><StatusDate>2003-12-31T00:00:00Z</StatusDate><SourceLink type="PR" id="884216"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="219">Mycobacterium leprae infection</Indication><StatusDate>1998-07-16T00:00:00Z</StatusDate><SourceLink type="OTHER" id="1484863"/></Row><Row><Company id="29253">Pharmion Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2003-10-13T00:00:00Z</StatusDate><SourceLink type="PR" id="517574"/></Row><Row><Company id="29253">Pharmion Corp</Company><Country id="IL">Israel</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2006-01-10T00:00:00Z</StatusDate></Row><Row><Company id="29253">Pharmion Corp</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2003-12-18T00:00:00Z</StatusDate><SourceLink type="PR" id="517521"/></Row><Row><Company id="29253">Pharmion Corp</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2006-12-12T00:00:00Z</StatusDate><SourceLink type="PR" id="750924"/></Row><Row><Company id="29253">Pharmion Corp</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2006-01-10T00:00:00Z</StatusDate></Row><Row><Company id="29253">Pharmion Corp</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2006-06-04T00:00:00Z</StatusDate><SourceLink type="PR" id="671186"/></Row><Row><Company id="29253">Pharmion Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="219">Mycobacterium leprae infection</Indication><StatusDate>2003-10-13T00:00:00Z</StatusDate><SourceLink type="PR" id="517574"/></Row><Row><Company id="29253">Pharmion Corp</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortorder="14">Registered</DevelopmentStatus><Indication id="219">Mycobacterium leprae infection</Indication><StatusDate>2003-12-18T00:00:00Z</StatusDate><SourceLink type="PR" id="517521"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><SourceLink type="PR" id="534292"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2002-04-26T00:00:00Z</StatusDate><SourceLink type="PR" id="884216"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="219">Mycobacterium leprae infection</Indication><StatusDate>2002-04-26T00:00:00Z</StatusDate><SourceLink type="PR" id="884216"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="219">Mycobacterium leprae infection</Indication><StatusDate>1997-09-08T00:00:00Z</StatusDate><SourceLink type="PR" id="261846"/></Row><Row><Company id="29253">Pharmion Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2002-07-26T00:00:00Z</StatusDate><SourceLink type="PR" id="459270"/></Row><Row><Company id="29253">Pharmion Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2002-04-26T00:00:00Z</StatusDate><SourceLink type="PR" id="449576"/></Row><Row><Company id="29253">Pharmion Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="219">Mycobacterium leprae infection</Indication><StatusDate>2002-07-26T00:00:00Z</StatusDate><SourceLink type="PR" id="459270"/></Row><Row><Company id="29253">Pharmion Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="PR" sortorder="13">Pre-registration</DevelopmentStatus><Indication id="219">Mycobacterium leprae infection</Indication><StatusDate>2002-04-26T00:00:00Z</StatusDate><SourceLink type="PR" id="449576"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="10">AIDS related complex</Indication><StatusDate>1994-10-13T00:00:00Z</StatusDate><SourceLink type="PR" id="190146"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2000-05-26T00:00:00Z</StatusDate><SourceLink type="CONFERENCE" id="368427"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate>2003-02-27T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="480943"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>1994-12-31T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="177618"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2006-06-02T00:00:00Z</StatusDate><SourceLink type="PR" id="884216"/></Row><Row><Company id="29253">Pharmion Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2004-05-20T00:00:00Z</StatusDate><SourceLink type="PR" id="539437"/></Row><Row><Company id="29253">Pharmion Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortorder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2006-06-02T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="671245"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2010-06-21T00:00:00Z</StatusDate><SourceLink type="TRIALREG" id="1199356"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2000-08-14T00:00:00Z</StatusDate><SourceLink type="PR" id="378813"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate>1999-04-16T00:00:00Z</StatusDate><SourceLink type="PR" id="321407"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2454">Glioblastoma</Indication><StatusDate>1999-05-31T00:00:00Z</StatusDate><SourceLink type="PR" id="325065"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2004-03-15T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="587744"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1264">Macroglobulinemia</Indication><StatusDate>2012-06-30T00:00:00Z</StatusDate><SourceLink type="TRIALREG" id="1437791"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="205">Melanoma</Indication><StatusDate>2002-05-22T00:00:00Z</StatusDate><SourceLink type="PR" id="452129"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="4250">Metastatic renal cell carcinoma</Indication><StatusDate>2001-04-26T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="407105"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="276">Prostate tumor</Indication><StatusDate>2000-12-01T00:00:00Z</StatusDate><SourceLink type="PR" id="389346"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate>2001-04-26T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="407105"/></Row><Row><Company id="29253">Pharmion Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2001-11-19T00:00:00Z</StatusDate><SourceLink type="PR" id="429721"/></Row><Row><Company id="29253">Pharmion Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2001-11-19T00:00:00Z</StatusDate><SourceLink type="PR" id="429721"/></Row><Row><Company id="29253">Pharmion Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortorder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2005-05-31T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="602357"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortorder="9">Clinical</DevelopmentStatus><Indication id="1143">Amyloidosis</Indication><StatusDate>2000-11-30T00:00:00Z</StatusDate><SourceLink type="PR" id="389346"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortorder="9">Clinical</DevelopmentStatus><Indication id="2454">Glioblastoma</Indication><StatusDate>1999-02-28T00:00:00Z</StatusDate><SourceLink type="PR" id="316211"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortorder="9">Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2003-06-30T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="493122"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortorder="9">Clinical</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>1994-12-31T00:00:00Z</StatusDate><SourceLink type="SERIAL" id="177618"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortorder="9">Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2003-03-21T00:00:00Z</StatusDate><SourceLink type="PR" id="483052"/></Row><Row><Company id="15331">Celgene Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortorder="7">Discovery</DevelopmentStatus><Indication id="768">Behcets disease</Indication><StatusDate>1997-10-30T00:00:00Z</StatusDate><SourceLink type="PR" id="264366"/></Row><Row><Company id="29253">Pharmion Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2004-03-15T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="587744"/></Row><Row><Company id="29253">Pharmion Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="NDR" sortorder="3">No Development Reported</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2004-03-15T00:00:00Z</StatusDate><SourceLink type="CORPORATE" id="587744"/></Row></DevelopmentStatusHistoric></Drug></Drugs>